Pulmonary metastasis of giant cell tumor of bones

Aikeremujiang Muheremu and Xiaohui Niu*

Abstract

Giant cell tumor of bone (GCTB) accounts for 5% of primary skeletal tumors. Although it is considered to be a benign lesion, there are still incidences of pulmonary metastasis. Pulmonary metastasis of GCTB may be affected by tumor grading and localization as well as the age, gender and overall health status of the patient. Patients with local recurrence are more likely to develop pulmonary metastasis of GCTB. High expression of some genes, cytokines and chemokines may also be closely related to the metastatic potential and prognosis of GCTB. The treatment of the primary GCTB is key to the final outcome of the disease, as intralesional curettage has a significantly higher local recurrence and pulmonary metastasis rate than wide resection. However, even patients with pulmonary metastasis seem to have a good prognosis after timely and appropriate surgical resection. It is hoped that with the development of novel surgical methods and drugs, pulmonary metastasis of GCTB can be prevented and treated more effectively.

Keywords: Giant cell tumor, Bone, Pulmonary metastasis

Review

Giant cell tumor of bone (GCTB) is a primary intramedullary tumor which is supposedly benign but can be locally aggressive and even metastatic [1-3]. Its name originated from the giant cells found within the tumor. Those giant cells share specific markers with osteoclasts such as tartrate-resistant acid phosphatase [4], cathepsin K [5], carbonic anhydrase II [6], calcitonin receptor [7] and receptor activator of nuclear factor-κB (RANK) [8]. They both have bone resorption capabilities, but giant cells are significantly larger than the osteoclasts and have hundreds of nuclei [9].

GCTB account for 5% of primary skeletal tumors and 21% of all benign bone tumors [10,11]. It has the highest prevalence among the population aged between 20 and 40-years-old and has a slight female predominance [12], with the female to male ratio of 1.3 to 1.5:1:0 [13]. The most usual sites for GCT include distal femur, proximal tibia and distal radius [14-18]. The incidence of GCTs in small bones is less than 1% of all GCT cases [19,20].

Diagnosis of giant cell tumor of bone

Conventional diagnostic methods of GCTB include its clinical, radiological and histopathological manifestations. Diagnostically, typical clinical manifestations of GCTB include regional pain, swelling and occasionally history of pathological fracture [21]. Radiographs demonstrate an eccentric lytic lesion with cortical extension. Histologically, GCT consists of multiple multinucleated giant cells with strong phenotypic similarities to osteoclasts and spindle-shaped proliferative stromal cells [15,22].

More recently, the increasingly popular application of novel imaging techniques such as positron emission tomography/computerized tomography (PET/CT) has made the diagnosis of primary and metastatic GCTB more accurate [23]. Furthermore, basic research has also provided diagnostic gene markers such as P53, P63 and P73 [24,25], as well as KTN 1, NEB, ROCK1 and ZAK [26]. However, more research is needed before these biomarkers can be used in clinical practice.

Pulmonary metastasis of giant cell tumor of bone

Prevalence

Although rare, GCTB can be multicentric or arise in locations where it is difficult to be surgically removed. The
course of progression of GCTB varies and can range from local bony destruction to local metastasis. The distant metastasis and malignant transformation are extremely rare conditions [27]. Rare cases of metastases to other sites have been described in the literature. Those reported include the lung, lymph nodes [28], liver, soft tissue [29], brain, mediastinum, scalp, kidney and penis.

Based on the current literature, approximately 3% of GCTB metastasizes to the lung (Table 1). Pulmonary metastasis is very rarely discovered during diagnosis of the initial GCTB, but more frequently in cases of recurrence. The interval from the time of surgery on the primary lesion to the occurrence of pulmonary metastasis can be as little as several months or more than 10 years. However, in most cases metastases were found within three years after the surgical treatment of the initial lesion [30,31]. Based on the current literature (Table 1), approximately 3% of GCTB metastasizes to lung at certain time points after the confirmed diagnosis of primary GCTB.

Factors related to the pulmonary metastasis of giant cell tumor of bone

There is no consensus on which factors may affect the likelihood of pulmonary metastasis of GCTB. However, several independent studies on some special types of GCTB may bring some insights into this issue. For example, Faisham et al. [39] have reported a pulmonary metastasis ratio of 30% in patients with grade 3 GCTB by Campanacci’s classification, indicating that the tumor grading might be an important prognostic factor for the prediction of pulmonary metastasis of GCTB. Donthineni et al. [38] have reported a pulmonary metastasis ratio of 13.7% in patients with GCTB which occur primarily on spine, and Errani et al. [32] reported a higher incidence of pulmonary metastasis of GCTB located in proximal femur and distal radius, indicating that the location of primary lesion might also be a prognostic factor. However, most authors believe that there is no significant relationship between the location of GCTB and its risk of pulmonary metastasis.

Rock et al. [47] had reported a six-fold higher risk of lung metastasis in patients who experienced local recurrence of GCTB compared with patients with no history of local recurrence. Studies by Rock and several other authors indicate that higher risk patients with recurrent GCTB should be carefully monitored for pulmonary metastases after the appropriate treatment of the recurrent lesion (Table 2). Most studies assume that local recurrence of GCTB is a risk factor for lung metastasis.

Moreover, literature of basic research has also provided us with methods to predict the possibility of pulmonary metastasis. For example, pro-osteoclastogenic

---

**Table 1** Some studies on pulmonary metastasis of giant cell tumors of bone

| Study (Author/year) | Time of follow up | Number of patients | Ratio of pulmonary metastasis |
|---------------------|------------------|--------------------|------------------------------|
| Errani et al. 2010 [32] | 91 (36-204) months | 349 | 4% |
| Kremen et al. 2012 [33] | 0.1-312 months | 230 | 2% |
| Takeuchi et al. 2011 [34] | 2-180 months | 110 | 7.5% |
| Klenke et al. 2011 [35] | 108 (36-233) months | 118 | 4.2% |
| Viswanathan et al. 2010 [36] | 4 months-12 years | 470 | 1.7 |
| Balke et al. 2008 [37] | 60 (8-280) months | 214 | 3.3% |
| Donthineni et al. 2006 [38] | 18-126 months | 51 | 13.7% |
| Faisham et al. 2006 [39] | 12-60 months | 20 | 30% |
| Dominkus et al. 2006 [30] | 3 months to 11.9 years | 649 | 2.1% |
| Prosser et al. 2005 [40] | 70 (24-214) months | 137 | 1.6% |
| Su et al. 2004 [41] | 62 (28-138) months | 87 | 1.2% |
| Trieb et al. 2001 [42] | 11 (4-43) years | 47 | 0% |
| Blackley et al. 1999 [43] | 80 (29-132) months | 59 | 1.7% |
| O’Donnell et al. 1994 [44] | 4 (2-10) years | 60 | 0% |
| Kay et al. 1994 [45] | 23-120 months | 66 | 9.1% |
| Campanacci et al. 1986 [1] | 2-44 years | 280 | 2.1% |
| McDonald et al. 1986 [46] | 84 (min 24) months | 146 | 3.2% |

---

**Table 2** Studies involving the relationship between local recurrence and pulmonary metastasis of GCTB

| Study (Author/year) | Number of patients | Number of patients with pulmonary metastasis | Local recurrence |
|---------------------|--------------------|---------------------------------------------|-----------------|
| Kremen et al. 2012 [33] | 230 | 5 | 28 |
| Klenke et al. 2011 [35] | 118 | 5 | 24 |
| Erani et al. 2010 [32] | 349 | 14 | 52 |
| Prosser et al. 2005 [40] | 137 | 22 | 26 |
| Trieb et al. 2001 [42] | 47 | 0 | 11 |
| Blackley et al. 1999 [43] | 59 | 10 | 12 |
| Kay et al. 1994 [45] | 66 | 6 | 18 |
| O’Donnell et al. 1994 [44] | 60 | 0 | 15 |
| Viswanathan et al. 2010 [36] | 470 | 8 | 13 of 24 patients with lung metastasis |
| Tubb et al. 1992 [48] | 7 | 13 of 13 patients with lung metastasis |
| Goldenberg et al. 1970 [28] | 218 | 6 | 5 of 6 patients with lung metastasis |
cytokines such as receptor activator of nuclear factor kappa-B ligand (RANKL), interleukin (IL)-6 and tumor necrosis factor (TNF), as well as monocyte-recruiting chemokines such as stromal cell-derived factor-1 (SDF-1) and monocyte chemoattractant protein (MCP)-1, participate in unfavorable osteoclastogenesis and bone destruction [49]. High expression of those cytokines and chemokines may help predicting the metastatic potential and prognosis of GCTB.

Treatment
Treatment of giant cell tumor of bone is still one of the most controversial and discussed issues [50]. The course of progression of metastatic pulmonary disease has been found to be as unpredictable as the primary tumor [51]. Since the incidence of pulmonary metastasis of GCTB is rather rare, there is no study on the systematic treatment of metastatic GCTB in the current literature. However, since the recurrence rate of GCTB is significantly related to its pulmonary metastasis, studies concerning treatment methods and the recurrence rate of GCTB may provide guidance for the prevention of metastasis and achieve a better prognosis.

Surgical treatment
Surgical treatment options for primary GCTB lesions include intralesional surgery and wide resection. Intralesional surgery has a higher recurrence rate but does preserve adjacent joint function. On the other hand, although wide resection may prevent metastasis, it may seriously impair the function of adjacent joints. When curettage is performed, local adjuvants such as polymethylmethacrylate (PMMA), phenol, alcohol, cryotherapy and hydrogen peroxide have been reported to significantly decrease the rate of local recurrence and pulmonary metastasis [10,11,38,52,53]. However, some other studies [40,54] failed to find any positive therapeutic effect of these adjacent measures. In a Scandinavian Sarcoma Group multicentric study by Kivioja et al. [11] involving 294 patients, the recurrence rate of GCTB was 20% in patients treated with bone cement, which is significantly lower ($P = 0.001$) than the 56% recurrence rate in patients who underwent

| Study (Author/year) | Number of patients | Wide resection | Intralesional curettage | Intralesional curettage + regional burring | Intralesional curettage + local adjuvants + PMMA |
|---------------------|-------------------|----------------|------------------------|------------------------------------------|-----------------------------------------------|
| Klenke et al. 2011 [35] | 118 | 5 | N/A | 32 | + phenol + burring:15 |
| Errani et al. 2010 [32] | 349 | 12 | N/A | 18 | |
| Balke et al. 2008 [37] | 214 | 0 | 140 | 47 | + phenol:38 |
| Kivioja et al. 2008 [11] | 294 | 12 | 51 | N/A | 22 |
| Knochenhutrenoren 2008 [52] | 256 | 2 | 49 | N/A | + phenol69 |
| Malek et al. 2006 [56] | 40 | N/A | N/A | 33 | N/A |
| McGough et al. 2005 [57] | 183 | N/A | 46 | N/A | N/A |
| Prosser et al. 2005 [40] | 137 | 0 | N/A | N/A | + burring:21 |
| Su et al. 2004 [41] | 87 | 3 | N/A | N/A | + phenol:18 |
| Turcotte et al. 2002 [55] | 186 | 34 | N/A | N/A | + phenol + burring:55 |
| Blackley et al. 1999 [43] | 59 | N/A | N/A | 12 | N/A |
| Campanacci et al. 1987 [1] | 280 | 0 | 27 | N/A | 8 |
| McDonald 1986 [45] | 146 | 7 | N/A | 34 | N/A |

Results from the current literature implies that the recurrence ratio of GCT is: Intralesional curettage > Intralesional curettage + regional burring > Intralesional curettage + local adjuvants + PMMA > Wide resection.

| Study (Author/year) | Number of patients | Cases with pulmonary metastasis | Survivors at the last follow up |
|---------------------|-------------------|-------------------------------|-------------------------------|
| Kremen et al. 2012 [33] | 230 | 5 | 4 |
| Takeuchi et al. 2011 [34] | 110 | 8 | 8 |
| Errani et al. 2010 [32] | 349 | 14 | 10* |
| Klenke et al. 2011 [35] | 118 | 5 | 4 |
| Viswanathan et al. 2010 [36] | 470 | 8 | 8 |
| Faisham et al. 2006 [39] | 20 | 6 | 5 |
| Dominkus et al. 2006 [30] | 649 | 14 | 14 |
| Donthineni et al. 2006 [38] | 51 | 7 | 5 |
| Kay et al. 1994 [45] | 7 | 7 | 6 |

*3 of the 4 patients died of causes irrelevant to GCTB.
intralesional surgery with bone grafts. On the contrary, in a Canadian multicentric study of 186 patients by Turcotte et al. [55], filling the remnant cavity with bone cement did not significantly reduce the recurrence rate of GCTB (Table 3).

Moreover, Enneking’s and Campanacci’s classifications [2,58] are helpful tools for planning the initial surgical treatment. For instance, stage III GCTB is best managed with wide resection for better local control. Faisham et al. [39] proposed that aggressive treatment of pulmonary metastasis is mandatory in the management of aggressive GCTB. Surgical excision of solitary and surgically-accessible lesions as well as lung metastases is now widely accepted as the treatment of choice, with an acceptable long-term survival rate [45].

Drug treatment
The anti-osteoclastic effects of bisphosphonates, along with their ability to protect bone from further resorption,
make bisphosphonates potential candidates for the treatment of GCTB, and studies have confirmed their efficacy [59]. Balke et al. [37] examined clinical and radiological outcomes of treatment with amino bisphosphonates on 25 cases of aggressive primary, recurrent and metastatic GCTB derived from four European centers. Most inoperable sacral or pelvic tumors did not increase in size and no further recurrence or metastasis was observed in patients with recurrent GCTB. Lung metastases did not increase in size or number following treatment, suggesting that bisphosphonates may be useful against the progression of metastatic GCTB lesion in lung.

Denosumab, a fully human monoclonal antibody that specifically inhibits normal and tumor-associated bone lysis by preventing RANKL-mediated formation and activation of multinucleated osteoclasts or giant cells from RANK-positive mono-nuclear preosteoclasts and
macrophages [21], has been proved to be able to reduce the number of RANK-positive giant cells and proliferative stromal cells [15]. In the study of Thomas et al. [60], 30 out of 35 (86%; 95% CI 70 to 95) of evaluable patients had a positive tumor response after the treatment of denosumab. It is likely a novel and effective method with great potential in the treatment of GCTB [61].

*Figure 4* She was treated with *en bloc* resection under the aid of computer navigation under intraoperative CT scan, and the cavity was filled with bone cement. Intraoperative pathological exam confirmed the recurrence of GCTB.
Prognosis
For lung metastasis, appropriate surgical resection such as metastasectomy, wedge resection or lobectomy should be carried out if it is possible to prevent progressive pulmonary dysfunction [30,62]. Because pulmonary metastases are rare and timely surgical and chemotherapeutic treatment is usually successful (Table 4, see Figures 1, 2, 3, 4, 5 and 6 for an example case), we believe the potential for metastases should not by itself be an indication for wide resection of primary tumors.

Conclusions
In conclusion, GCTB is normally considered a benign bone tumor. However, it may occasionally metastasize to vital organs such as the lung. The prognosis can be successful with timely and appropriate surgical treatment and chemotherapy. With the development of novel surgical methods and application of new drugs, most patients with GCTB can still achieve successful treatment results.

Abbreviations
CT: computerized tomography; GCTB: Giant cell tumor of bone; IL: interleukin; MRI: magnetic resonance imaging; MCP: monocyte chemoattractant protein; PMMA: polymethylmethacrylate; PET/CT: positron emission tomography/computed tomography; RANK: receptor activator of nuclear factor-κB; RANKL: receptor activator of nuclear factor kappa-B ligand; SDF: stromal cell-derived factor-1; TNF: tumor necrosis factor.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Dr A.M searched for the papers, extracted the research data from those papers and drafted the manuscript. Dr X.N checked the structure of the manuscript, provided the patient file and figures of the patients he has treated. Both authors read and approved the final manuscript.

Received: 30 January 2014 Accepted: 6 August 2014 Published: 20 August 2014

References
1. Campanacci M, Baldini N, Boriani S, Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am 1987, 69:106–114.
2. Enneking WF: Musculoskeletal Tumor Surgery. New York (NY): Churchill Livingstone, Inc.; 1983.
3. Feigenberg SJ, Marcus RB, Zlotecki RA, Scarborough MT, Enneking WF: Whole-lung radiotherapy for giant cell tumors of bone with pulmonary metastases. Clin Orthop Relat Res 2002, 401:202–208.
4. Anazawa U, Hanaoka H, Shiraishi T, Morioka H, Morii T, Toyama Y: Similarities between giant cell tumor of bone, giant cell tumor of tendon sheath, and pigmented villonodular synovitis concerning ultrastructural cytochemical features of multinucleated giant cells and mononuclear stromal cells. Ultrastruct Pathol 2006, 30:151–158.
5. Lindeman JH, Hanemaaijer R, Mulder A, Dijkstra PD, Suhai K, Bromme D: Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol 2004, 165:593–600.
6. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I: Interleukin-6 and soluble interleukin-6 receptors in the synovialfluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996, 11:89–95.
7. Collier FM, Huang WH, Holloway WR, Hodge JM, Gillespie MT, Daniels LL: Osteoclasts from human giant cell tumors of bone lack estrogen receptors. Endocrinology 1998, 139:1258–1267.
8. Atkins GJ, Kostakis P, Vincent C, Farrugia AN, Houchins JP, Findlay DM, Evdokiou A, Zannettino AC: RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2005, 21:1339–1349.
9. Baile M, Campanacci L, Gebert C, Peci P, Gibbons M, Taylor R, Hogendoorn P, Kroep J, Wiss J, Athanasiou N: Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer 2010, 10:462.
10. Lackman RD, Hosalkar HS, Ogilvie CM, Torbert JT, Fox EJ. Intralesional curettage for grades II and III giant cell tumors of bone. Clin Orthop Relat Res 2005, 438:123-7.

11. Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Wallow A, Bauer HC, Jorgensen PH, Berg P, Forlinder C: Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 2008, 79:86–93.

12. Harms NG, Mankin HJ. Giant-cell tumor of the distal forearm. J Hand Surg 2003, 29A:188 e93.

13. Jin CM, So RK, Myung JC, Yong CL. Multiple pulmonary metastases from giant cell tumor of a hand. Am J Med Sci 2012, 343(1):171-173.

14. Huvos AG. Tumors of histiocytic or fibrohistiocytic origin: giant cell tumor of bone. In Bone Tumor. Diagnosis, Treatment, and Prognosis. 2nd edition. Edited by Huvos AG. Philadelphia: WB Saunders; 1991:429–467.

15. Kim TS, Park JS. Metastasising recurrent giant cell tumor: a case report. J Korean Bone Joint Tumor Soc 2001, 1:73–79.

16. Mina JM. Giant-cell tumors. In Bone Tumors: Clinical, Radiological, and Pathologic Correlations. Edited by Mina JM. Philadelphia: Lea and Febiger; 1989:941–1020.

17. Osaka S, Sugita H, Osaka E, Yoshida Y, Ryu J, Hemmi A, Suzuki K. Clinical and immunohistochemical characteristics of benign giant cell tumor of bone with pulmonary metastases: case series. Orthop Surg (Hong Kong) 2004, 12:55–62.

18. Siebenrock KA, Unni KK, Rock MG. Giant-cell tumor of bone metasatssising to the lungs: a long-term follow-up. J Bone Joint Surg (Br) 1998, 80:43–47.

19. Averill RM, Smith RJ, Campbell CJ. Giant cell tumors of the bones of the hand. J Hand Surg Am 1980, 5:39–50.

20. Popans M, Kaila R, Cannon SR, Briggs TW. Primary giant cell tumours of the digital bones of the hand. J Hand Surg 2007, 32B:160 e4.

21. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Byl J, Rouzier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Natural history of giant cell tumors of bone: a case-control study. Am J Clin Orthop Relat Res 2010, 484:62–66.

22. Warner M. Giant cell tumor of bone: morphological, biological and histogenetical aspects. Int Orthop 2006, 30:484–485.

23. Tian R, Su M, Tian Y, Li L, Lu Q. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions. Skeletal Radiol 2009, 38:451–458.

24. Cowan RW, Singh G. Giant cell tumor of bone: a basic science perspective. Bone 2013, 52:238–246.

25. Vincenzo G, Vincenzo DL. Role of p63 in cancer development. Biochim Biophys Acta 1816, 2011:57–66.

26. Roberto A, Luis A, Curado V, Peitl P, Zuccari D. Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy. Eur J Surg Oncol 2001, 27:200–202.

27. Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am 1999, 81A:811–820.

28. D’Onofrio RJ, Springfield DS, Motwani HK, Ready JE, Gebhardt MC, Mankin HJ. Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 1994, 76:1827–1833.

29. Kay RM, Eckardt JJ, Seeger LL, Mina JM, Hak DJ. Pulmonary metastasis of benign giant cell tumor of bone: six histologically confirmed cases, including one of spontaneous regression. Clin Orthop 1994, 302:219–230.

30. McDonald DJ, Sim FH, McLeod RA, Dahlin DC. Giant-cell tumor of bone. J Bone Joint Surg Am 1986, 68:235–242.

31. Rock MG. Curettage of giant-cell tumor of bone: factor influencing local recurrences and metastases. Curr Opin Oncol 2001, 13:Suppl. 1:204–205.

32. Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone. J Bone Joint Surg Am 2003, 85:1187–1192.

33. Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 2008, 42:68–73.

34. Campanacci M. Bone and Soft Tissue Tumors. 2nd edition. New York, NY: Springer; 1999.

35. Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 2008, 42:68–73.

36. Bannerstedt DG, Nelson SD, Manivel JC, Blay J, Chawla S, Thomas DM, Jun S, Jacobs I. Denosumab induces tumor reduction and bone metastasis in a preclinical model of giant cell tumor of bone. Clin Orthop Relat Res 2014, 472:657–683.
formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012, 18:4415–4424.
61. Hamann C, Lützner J, Wieczorek K, Hofbauer LC: Pulmonary metastases due to a giant-cell tumor of bone. J Clin Endocrinol Metab 2012, 97:3408–3409.
62. Gupta R, Seethalakshmi V, Jambhekar NA, Prabhudesai S, Merchant N, Puri A, Agarwal M: Clinicopathologic profile of 470 giant cell tumors of bone from a cancer hospital in western India. Ann Diagn Pathol 2008, 12:239–248.

doi:10.1186/1477-7819-12-261
Cite this article as: Muheremu and Niu: Pulmonary metastasis of giant cell tumor of bones. World Journal of Surgical Oncology 2014 12:261.